NGS-Based RNA-Sequencing Market Report 2025

This NGS-Based RNA-Sequencing report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The NGS-based RNA-sequencing market size has grown exponentially in recent years. It will grow from $3.41 billion in 2024 to $4.23 billion in 2025 at a compound annual growth rate (CAGR) of 24.2%. The growth in the historic period can be attributed to genomic research initiatives, reduction in sequencing costs, drug discovery and development, personalized medicine, increasing ngs adoption.

The NGS-based RNA-sequencing market size is expected to see exponential growth in the next few years. It will grow to $10.4 billion in 2029 at a compound annual growth rate (CAGR) of 25.2%. The growth in the forecast period can be attributed to clinical diagnostics, global collaborations, ethical and regulatory frameworks, agricultural and environmental research, green genomics. Major trends in the forecast period include single-cell rna-sequencing (scrna-seq), spatial transcriptomics, epitranscriptomics, multi-omics integration, sustainable agriculture.

The expansion of precision medicine is propelling the growth of the NGS-based RNA sequencing market. Precision medicine assists healthcare providers in creating tailored treatment plans and making decisions based on a genetic understanding of the patient's condition. There is an increasing focus on precision medicines for addressing serious diseases such as cancer. NGS-based RNA sequencing is instrumental in identifying the underlying causes of diseases and recommending specific precision treatments. For example, in February 2023, a report from the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, indicated that personalized medicines represented 35% of newly approved New Molecular Entities (NMEs) in 2021. With 12 new approvals in 2022, they have consistently accounted for at least a quarter of new drug approvals over the past eight years, marking a substantial rise from less than 10% a decade ago. As the demand for precision medicines continues to grow, so too will the demand for NGS-based RNA sequencing.

The expanding pharmaceutical industry is anticipated to drive the growth of the NGS-based RNA sequencing market in the future. The pharmaceutical industry encompasses the discovery, development, and production of drugs and medicines by both public and private organizations. NGS-based RNA sequencing is utilized within this sector to conduct thorough analyses of gene expression, identify potential drug targets, evaluate drug responses, and comprehend disease mechanisms, thereby enhancing drug discovery and development through a better understanding of molecular processes. For instance, in September 2024, statistics published by Cross River Therapy, a US-based provider of ABA therapy services, revealed that the U.S. pharmaceutical industry generated $550 billion in revenue, with Americans spending $576.9 billion on medications in 2021. Projected spending is expected to rise to between $605 billion and $635 billion by 2025. Consequently, the growth of the pharmaceutical industry is propelling the expansion of the NGS-based RNA sequencing market.

A notable trend in the NGS-based RNA sequencing market is the formation of strategic partnerships. Companies are increasingly engaging in partnerships with NGS-based RNA sequencing firms to enter new markets and leverage collective resources. For instance, in May 2022, The Biomedical Advanced Research and Development Authority (BARDA) partnered with multiple industry and academic collaborators to enhance diagnostic capabilities for respiratory RNA viruses. Such strategic partnerships contribute to bolstering the capacity to respond swiftly to public health emergencies and advance diagnostic capabilities.

Major companies in the NGS-based RNA-sequencing market are concentrating on innovative products to meet the growing demand for RNA sequencing. One such innovation is the development of ultra-fast RNA methods for molecular testing and life science research applications, offering exceptionally rapid RNA sequencing or analysis. In March 2022, Quantabio launched the sparQ RNA-Seq HMR Kit, an ultra-fast RNA library preparation tool designed for precision oncology applications. This kit enables the generation of high-quality NGS sequencer-ready libraries from intact or degraded samples in a single day.

In October 2022, Illumina Inc., a US-based company specializing in DNA sequencing and array-based technology, announced a collaboration with GenoScreen. This partnership seeks to enhance access to genomic testing for multidrug-resistant tuberculosis (MDR-TB), facilitating faster and more effective detection of drug resistance to aid in the global fight against TB, particularly in countries severely affected by the disease. GenoScreen is a France-based company focused on sequencing, genotyping, and bioinformatics.

Major companies operating in the ngs-based rna-sequencing market include Illumina Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies Ltd., Agilent Technologies Inc., BGI Group, QIAGEN N.V., PerkinElmer Inc., Eurofins Scientific SE, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hamilton Company, Takara Bio Inc., Tecan Trading AG, GENEWIZ Inc., Novogene Corporation, Macrogen Inc., Zymo Research Corp., Lexogen GmbH, Partek Incorporated, GATC Biotech AG, Becton, Dickinson and Company, Genohub LLC, BaseClear B.V., Genewave SAS, Otogenetics Corporation, SeqLL LLC, GenXPro GmbH, Genotypic Technology Pvt. Ltd.

North America was the largest region in the NGS-based RNA sequencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in NGS-based RNA sequencing market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the NGS-based RNA sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

NGS-based RNA-sequencing is a technique employed to identify and quantify the amount of ribonucleic acid (RNA) present in a biological sample at a specific moment, utilizing next-generation sequencing (NGS). Next-generation sequencing, characterized by massively parallel sequencing technology, offers exceptionally high throughput, scalability, and speed, allowing for the determination of nucleotide sequences in whole genomes or specific DNA/RNA segments.

The primary products and services associated with NGS-based RNA sequencing include sample preparation products, sequencing platforms and consumables, sequencing services, and data analysis, storage, & management. Sample preparation products facilitate the adherence of DNA or RNA to the sequencing flowcell, enabling sample identification. The sample preparation process involves converting nucleic acid mixtures from biological samples into various libraries, preparing them for NGS technologies. Technologies involved in NGS encompass sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing. These sequencing methods find application in expression profiling analysis, small RNA sequencing, de novo transcriptome assembly, variant calling, and transcriptome epigenetics. NGS-based RNA-sequencing is utilized by a range of end users, including research & academia, hospitals & clinics, pharmaceutical & biotechnology companies, and other entities in the scientific community.

The NGS-based RNA sequencing market research report is one of a series of new reports that provides NGS-based RNA sequencing market statistics, including NGS-based RNA sequencing industry global market size, regional shares, competitors with a NGS-based RNA sequencing market share, detailed NGS-based RNA sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the NGS-based RNA sequencing industry. This NGS-based RNA sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The NGS-based RNA-sequencing market includes revenues earned by ribosomal RNA (rRNA), transfer RNA (tRNA), long ncRNA and many smaller ncRNAs such as microRNA. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.